|
EP3810146A1
|
|
Otic formulations for drug-induced ototoxicity
|
|
WO2019140012A1
|
|
Growth factor otic formulations
|
|
WO2019126783A1
|
|
Triglyceride otic formulations and uses thereof
|
|
EP3573636A2
|
|
Neurotrophin mutants for treating hearing loss and other otic disorders
|
|
EP3518929A1
|
|
Otic gel formulations for treating otitis media
|
|
US2018085304A1
|
|
Otic gel formulations for treating otitis externa
|
|
CN109689027A
|
|
Triglycerides aural preparations and application thereof
|
|
WO2017100576A1
|
|
Ciprofloxacin otic composition and kits and method for using same
|
|
AU2016228201A1
|
|
Auris formulations for treating otic diseases and conditions
|
|
EP3328440A1
|
|
Treatment using truncated trk b and trk c antagonists
|
|
CA2993645A1
|
|
Trkb or trkc agonist compositions and methods for the treatment of otic conditions
|
|
CA2956324A1
|
|
Otic formulations for the treatment of ceruminosis
|
|
CA2954170A1
|
|
Sterilization of ciprofloxacin composition
|
|
AU2014311358A1
|
|
Treatment of pediatric otic disorders
|
|
AU2014200457A1
|
|
Controlled release antimicrobial compositions and methods for the treatment of otic disorders
|
|
AU2013254940A1
|
|
Auris formulations for treating otic diseases and conditions
|
|
EP2675409A1
|
|
Prevention of and recovery from drug-induced ototoxicity
|
|
EP2490722A2
|
|
Modulation of gel temperature of poloxamer-containing formulations
|
|
ZA201007001B
|
|
Auris formulations for treating otic diseases and conditions
|
|
CN102112111A
|
|
Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
|
